Arlington Trust Co LLC Has $439,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Arlington Trust Co LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 15.3% in the 4th quarter, HoldingsChannel reports. The firm owned 3,034 shares of the company’s stock after buying an additional 403 shares during the period. Arlington Trust Co LLC’s holdings in Johnson & Johnson were worth $439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in JNJ. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $35,000. Bay Harbor Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.24 on Friday. The business’s 50-day moving average price is $147.58 and its 200-day moving average price is $156.00. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market capitalization of $378.58 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.46 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the firm posted $2.29 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Guggenheim increased their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.67.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.